Experienced in Pure Red Cell Aplasia

Dr. Vamsi K. Kota

Hematology Oncology | Transplant Surgery | Hematology
Wellstar Medical Group LLC
1120 15th St, 
Augusta, GA 
Accepting New Patients
18 Years of Experience
Experienced in Pure Red Cell Aplasia
Wellstar Medical Group LLC
1120 15th St, 
Augusta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vamsi Kota is a Hematologist Oncology specialist and a Transplant Surgeon in Augusta, Georgia. Dr. Kota has been practicing medicine for over 18 years and is rated as an Experienced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kota is currently accepting new patients.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Hematology
Licenses
Internal Medicine in GA
Hospital Affiliations
Wellstar Mcg Health, Affiliated With Med Col
Languages Spoken
English
Hindi
Mandarin
Spanish
Telugu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

WELLSTAR MEDICAL GROUP LLC
1120 15th St, Augusta, GA 30912
Other Locations
WELLSTAR MEDICAL GROUP LLC
5150 Stilesboro N W Rd, Suite 220, Kennesaw, GA 30152
WELLSTAR MEDICAL GROUP LLC
989 Saint Sebastian Way, Augusta, GA 30912

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Assessing Financial Difficulty in Patients with Blood Cancers
Assessing Financial Difficulty in Patients with Blood Cancers
Enrollment Status: Completed
Publish Date: January 17, 2025
Intervention Type: Other
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drugs: CDX-1140, CDX-301, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients With Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: The EMPATHY Pilot Study
Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients With Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: The EMPATHY Pilot Study
Enrollment Status: Completed
Publish Date: March 04, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
Enrollment Status: Unknown
Publish Date: March 21, 2019
Combination of Pioglitazone and Tyrosine Kinase Inhibitor (TKI) in Relapsed Chronic Myeloid Leukemia Following a First TKI Discontinuation
Combination of Pioglitazone and Tyrosine Kinase Inhibitor (TKI) in Relapsed Chronic Myeloid Leukemia Following a First TKI Discontinuation
Enrollment Status: Terminated
Publish Date: January 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
Assessing the Impact of a Simplified Patient Care Strategy to Decrease Early Deaths In Acute Promyelocytic Leukemia (APL) By Maintaining A Database
Assessing the Impact of a Simplified Patient Care Strategy to Decrease Early Deaths In Acute Promyelocytic Leukemia (APL) By Maintaining A Database
Enrollment Status: Terminated
Publish Date: December 10, 2018
First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: November 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

122 Total Publications

Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment.
Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment.
Journal: Future oncology (London, England)
Published: October 06, 2025
Similar Doctors
Abdullah Kutlar
Experienced in Pure Red Cell Aplasia
Dr. Abdullah Kutlar
Hematology Oncology | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Abdullah Kutlar
Hematology Oncology | Hematology | Oncology

Wellstar Medical Group LLC

989 Saint Sebastian Way, 
Augusta, GA 
 (0.3 miles away)
706-721-2171
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdullah Kutlar is a Hematologist Oncology specialist and a Hematologist in Augusta, Georgia. Dr. Kutlar is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemolytic Anemia, Congenital Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Kutlar is currently accepting new patients.

Experienced in Pure Red Cell Aplasia
Dr. Jorge E. Cortes-Franco
Hematology Oncology | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Jorge E. Cortes-Franco
Hematology Oncology | Hematology | Oncology

Wellstar Medical Group LLC

989 Saint Sebastian Way, 
Augusta, GA 
 (0.3 miles away)
706-721-2171
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jorge Cortes-Franco is a Hematologist Oncology specialist and a Hematologist in Augusta, Georgia. Dr. Cortes-Franco is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Childhood Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration. Dr. Cortes-Franco is currently accepting new patients.

Paul M. Dainer
Experienced in Pure Red Cell Aplasia
Dr. Paul M. Dainer
Hematology Oncology | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Paul M. Dainer
Hematology Oncology | Hematology | Oncology
Medical College Of Ga, Section Of Hem-onc ,baa-5407, 1120 15th St, 
Augusta, GA 
 (0.1 miles away)
706-733-0188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Dainer is a Hematologist Oncology specialist and a Hematologist in Augusta, Georgia. Dr. Dainer is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Langerhans Cell Histiocytosis, Pleuropulmonary Blastoma, Lung Cancer, Glioma, and Splenectomy. Dr. Dainer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kota's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 22 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile